Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Advances in psoriasis treatment: experts comment on recent developments.

Literature DB >> 24391402

Advances in psoriasis treatment: experts comment on recent developments.

Abstract

Part 1 covers promising biologics that aim to promote safety and efficacy in treating psoriatic lesions. Part 2 addresses the problem of nonadherence to treatment.

Entities: Disease

Year: 2013 PMID： 24391402 PMCID： PMC3875268

Source DB: PubMed Journal: P T ISSN： 1052-1372

23 in total

1. Psoriasis and risk of myocardial infarction.

Authors: Mario Malerba; Paolo Gisondi; Alessandro Radaeli; Giampiero Girolomoni
Journal: JAMA Date: 2007-01-24 Impact factor: 56.272

2. Adherence to adalimumab in patients with moderate to severe psoriasis.

Authors: Cameron West; Swetha Narahari; Jenna O'Neill; Scott Davis; Monica Huynh; Adele Clark; Ann Boles; Steven R Feldman
Journal: Dermatol Online J Date: 2013-05-15

3. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study.

Authors: A-M Tobin; R Hughes; E B Hand; T Leong; I M Graham; B Kirby
Journal: Clin Exp Dermatol Date: 2011-01 Impact factor: 3.470

4. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Authors: Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner
Journal: N Engl J Med Date: 2012-03-29 Impact factor: 91.245

5. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.

Authors: Jashin J Wu; Kwun-Yee T Poon; Jennifer C Channual; Albert Yuh-Jer Shen
Journal: Arch Dermatol Date: 2012-11

6. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Authors: Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Journal: Lancet Date: 2008-05-17 Impact factor: 79.321

7. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.

Authors: Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand
Journal: JAMA Dermatol Date: 2013-10 Impact factor: 10.282

8. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic.

Authors: Andreas Storm; Stig Ejdrup Andersen; Eva Benfeldt; Jørgen Serup
Journal: J Am Acad Dermatol Date: 2008-05-07 Impact factor: 11.527

9. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Authors: K A Papp; C E M Griffiths; K Gordon; M Lebwohl; P O Szapary; Y Wasfi; D Chan; M-C Hsu; V Ho; P D Ghislain; B Strober; K Reich
Journal: Br J Dermatol Date: 2013-04 Impact factor: 9.302

10. Psoriasis and Cardiovascular Risk: Assessment by CUORE Project Risk Score in Italian Patients.

Authors: Spyridoula Doukaki; Valentina Caputo; Maria Rita Bongiorno
Journal: Dermatol Res Pract Date: 2013-09-08

1 in total

1. Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis.

Authors: Qian Zou; Jiawei Si; Yatao Guo; Jiayu Yu; Huijuan Shi
Journal: J Int Med Res Date: 2021-03 Impact factor: 1.671

1 in total